We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





The New and the Next in Brain Health Biomarkers

By CLN Stat
Posted on 14 Dec 2020
The Journal of Applied Laboratory Medicine hot topics session spotlights labs’ role in identifying and managing neurodegeneration and brain injury.

Building on the January 2020 special collection issue on brain health biomarkers, this year’s Journal of Applied Laboratory Medicine (JALM) Hot Topics session spotlights new biomarker applications in neurological disease and highlights laboratories’ role in identifying and managing neurodegeneration and brain injury. More...
Knowledge about brain health is growing rapidly, in particular for Alzheimer’s disease and traumatic brain injury (TBI), Robert Christenson, PhD, editor-in-chief of JALM and professor of pathology and professor of medical and research technology at the University of Maryland School of Medicine in Baltimore, told CLN Stat.

Clinical laboratorians and other attendees at the 2020 AACC Annual Scientific Meeting should know and understand the current status and future promise of advances in these fields. “We believed that a session highlighting the information in JALM and recent findings on these fields would be of particular interest,” added Christenson.

Attendees will learn about the strengths and weaknesses of current TBI biomarkers for use at the point-of-care and in central laboratories, summarized co-presenter Mari DeMarco, PhD, DABCC, FCACB, a clinical associate professor in the department of pathology and laboratory medicine at the University of British Columbia. For Alzheimer’s disease biomarkers, attendees will be able to describe case criteria for appropriate use of testing and learn through a series of case presentations how to interpret core biomarkers for diagnosing Alzheimer’s disease and related disorders.

“Moreover, participants will gain an understanding of the current and evolving role of biomarkers in the development of novel therapeutics for neurodegenerative disorders,” added DeMarco.

Biomarker Utilization in Neurological Disease: a JALM Hot Topics Symposium features three presentations.

DeMarco will address cerebrospinal fluid biomarkers for Alzheimer’s disease. These core biomarkers “are recommended by the international community for diagnostics purposes under select circumstances and used in clinical care around the globe,” said DeMarco. “Beyond the core biomarkers, there are biomarkers in both blood and cerebrospinal fluid under investigation for complementary applications, including facilitating clinical trial enrollment—enriching for populations of interest—and monitoring response to therapy.”

Omar Laterza, PhD, DABCC, executive director for molecular biomarkers and diagnostics at Merck, plans to discuss the role of biomarkers in developing therapeutics that target Alzheimer’s and other neurological diseases. Christenson rounds out the session with a talk on the present and future status of TBI biomarkers.

For TBI, the U.S. Food and Drug Administration has cleared an assay as an aid in evaluating concussion. “However, the current platform for measurement is not ideal for rapid turnaround of results,” said Christenson. “Other indications for biomarkers in blood and other fluids are being actively developed.” Additional applications should be available in the near future. For Alzheimer’s disease, some clinical practices are measuring beta-amyloid 42 (major component of amyloid plaques), and tau and phosphorylated tau (major components of tau tangles in the brain).

This Hot Topics scientific session at the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo takes place on December 16 from 11 a.m.–12:30 p.m. U.S. Central Standard Time and is worth 1.5 ACCENT credit hours.

Related Links:
2020 AACC Annual Scientific Meeting
Biomarker Utilization in Neurological Disease: a JALM Hot Topics Symposium

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
STI Test
REALQUALITY RQ-SevenSTI
New
Mumps Test
ReQuest MUMPS IgM Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: A biomarker discovery pipeline has shown promise as a noninvasive method of diagnosing CRC (Photo courtesy of NCI Center for Cancer Research)

Machine Learning Tool Enables Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when considering both genders. Colonoscopy remains the gold standard for CRC diagnosis, but it is invasive,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.